Contact Us Privacy Statement Terms of Use Home For Patients
Neulasta® (pefgilgrastim). Start with support
Search Go
Important Product Safety Information
E-Mail to a Colleague
 
Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.